Delveinsight

FEBRUARY 23, 2021

The company plans to use the capital to expand its pipeline of protein-based vaccines and biologic cancer therapies utilizing its innovative and proprietary Trimer-Tag technology platform. The company develops transformative biologics including vaccines and therapeutics for the world’s most debilitating diseases.

In-Vitro 52

In-Vitro Vaccination Vaccine Licensing 52

XTalks

OCTOBER 12, 2022

Features of blood perfusion in the brain detected by MRI now have clinical applications in central nervous system (CNS) cancers, neurodegenerative disease, cerebrovascular disease and demyelinating disease. The other option is to tag just one of the feeder vessels to the liver, but that does not capture the full blood flow in the liver.”.

Clinical Trials 93

Clinical Trials Clinical Trials Trials Drugs 93

XTalks

SEPTEMBER 27, 2022

Skysona received FDA approval for the treatment of the rare neurological disorder cerebral adrenoleukodystrophy (CALD). CALD is a rare, progressive neurodegenerative disease that mainly affects young boys. The record-breaking price tag of Skysona is not surprising for one-time gene therapies like it. Related: Bluebird’s $2.8M

FDA Approval 52

FDA Approval Gene Therapy Drugs Gene 52